Consensus $320.6M. Sees U.S. Ocaliva net sales at $77M in Q4 and $285M in FY22. Comments taken from investor presentation slides at J.P. Morgan Healthcare Conference.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ICPT:
- Intercept announcse efficacy, safety data from Phase 3 REGENERATE study
- Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023
- Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH
- Intercept resubmits NDA for obeticholic acid in liver fibrosis due to NASH
- Trial success is rocketing this NASH stock higher and sinking these peers